ImmunityBio, Inc. Common Stock
Here’s whether ImmunityBio, Inc. Common Stock (IBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +138.6%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.38% over 10 days); 3-month momentum negative (-18.1%). Currently 44.3% off its 52-week high. Score: +0/7.
IBRX is holding above its long-term 200-day MA ($4.92) but has slipped below the 50-day MA ($7.56), pointing to short-term weakness in an otherwise intact trend. An RSI of 34.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +138.6% compares to +24.4% for SPY (beat the market by 114.3%). The current 44.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.